How to Choose a Local Agent for Overseas Registration of Rehabilitation Devices

Key Summary

The choice of local agent for overseas registration of rehabilitation devices directly affects whether a product can successfully enter the target market and whether certificate maintenance remains stable. Manufacturers should first confirm the regulatory status and risk class of the product in the target country, and then determine the statutory responsibilities of the local agent or authorized representative based on the registration pathway. Do not simply apply CE or FDA experience. During the preparation phase, assess whether existing technical documentation for NMPA, CE, FDA, ISO 13485, and MDSAP can be reused, while also verifying the applicability of labeling, instructions for use, performance validation, risk management, and clinical evaluation evidence. When selecting a local agent, verify their qualifications, scope of services, understanding of medical device regulations, communication records with regulatory authorities, and post-market surveillance capabilities. Common risks include incomplete agent qualifications, unclear division of responsibilities, loss of control over certificates, and lack of follow-up on changes and renewals. Manufacturers should clarify responsibility boundaries, data access rights, notification obligations for changes, and termination clauses in the agent agreement, establish a complete evidence chain, and retain original files to reduce the risk of deficiencies and delays in multi-country registrations.

For Chinese medical device manufacturers, a reliable approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Registration in a target market typically impacts technical files, authorized representative, importer cooperation, label language, quality system certificates, and subsequent change maintenance. If the project is advanced only by looking at 'which documents to submit', deficiencies or rework are likely to occur in model coverage, consistency of the evidence chain, label claims, and certificate control. AIMEILI recommends that manufacturers integrate this issue into the regulatory strategies of GHWP member countries and multi-country access planning, using a set of reusable core technical files to support local adaptation across different markets rather than redoing documentation for each country.

This article is based on the AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information. For specific projects, the latest requirements of the target country's regulatory authority and the product's documentation basis should prevail.

Applicable Scenarios and Core Issues

The selection of a local agent for overseas registration of rehabilitation devices is a common decision point for medical device manufacturers entering overseas markets. Rehabilitation devices covered here include rehabilitation training equipment, physical therapy devices, mobility aids, wheelchairs, nursing beds, home rehabilitation instruments, wearable electrical stimulation devices, and similar products. These products have greatly different structures and regulatory characteristics: some are active medical devices, some are non-active devices, and some may include software functionality or measuring functions.

Before selecting a local agent, manufacturers must clarify the regulatory requirements of the target market. Regulatory models vary greatly across North America, the European Union, GHWP member states, Southeast Asia, the Middle East, and Latin America. Some countries require a designated local agent or authorized representative, while others allow a foreign manufacturer to apply directly but require the appointment of a local license holder or agent to assume post-market surveillance responsibilities.

The core issue is not 'which agent is cheaper' but 'whether the agent can handle the technical communication, document submission, deficiency response, post-market reporting, and continue to maintain the certificate and fulfil regulatory obligations after obtaining approval'. When formulating an overseas registration plan, manufacturers should incorporate the local agent's role into the overall registration strategy rather than seeking one at the last minute.

Registration Judgment Logic

The premise of selecting a local agent is to first complete a judgment of the product's registration pathway in the target country.

• Step 1: Determine whether the product falls under the medical device regulatory scope in the target country. Definitions and classifications of medical devices may differ by country. Some rehabilitation devices may be regarded as ordinary consumer products or wellness devices (e.g., some low-risk rehabilitation equipment).
• Step 2: Determine the product risk class and registration pathway. For example, most GHWP member countries adopt risk-based classification systems such as A/B/C/D or I/II/III. These classes determine the registration procedure, technical documentation requirements, and review duration. Verify whether exemptions, fast-track pathways, or simplified procedures apply.
• Step 3: Evaluate whether existing documentation can be reused. If the manufacturer already holds NMPA registration, CE certificates, or FDA 510(k)/PMA, the technical files can serve as the basis, followed by local adaptation. ISO 13485 and MDSAP certificates help demonstrate QMS compliance but do not waive local registration requirements.
• Step 4: Clarify the specific role of the local agent. Some countries require a 'local agent' to be a company or individual registered in that country; others require an 'authorized representative' to be established in the EU or that country and to communicate with regulators. Confirm whether the role is needed only for the application phase or for the entire validity period of the certificate, and define the service duration and responsibility scope accordingly.
• Step 5: Analyze the multi-country registration scenario. Use a core technical file reuse approach, but note that administrative requirements, language, labeling, IFU, and registration format may still differ by country. A local agent can assist with local adaptation, but the manufacturer must retain control of original technical data and not rely entirely on the agent.

Documentation and Evidence

When selecting a local agent, carefully review the completeness of documentation for the registration dossier and make clear arrangements for the agent's participation in document preparation.

• Technical files: Product descriptions, specifications, working principles, materials, software descriptions (if any), packaging, and label drafts. These form the basis for registration applications and usually require translation into the target language.
• Risk management files: Documentation based on ISO 14971, including risk analysis, risk evaluation, risk control measures, and overall residual risk evaluation. Adjust according to the intended use and patient contact in the target market.
• Performance validation and clinical evaluation: Performance tests, electrical safety tests, EMC tests, biocompatibility assessments, etc. If the target country requires clinical data, prepare clinical evaluation reports or clinical trial documentation.
• Quality management system files: Certificates and procedure documents for ISO 13485, MDSAP, or local QMS requirements. Some countries may also require audit reports or factory inspection records.
• Labels and IFU: Must be in the target country language and comply with local rules on symbols, warnings, instructions, and traceability. The local agent should assist with language and layout specifications.
• Post-market surveillance documents: Adverse event reporting procedures, complaint handling records, recall processes, annual updates, and documents for renewal. The local agent must accept and report post-market obligations.

Notably, local agents are often involved in responses to deficiencies. Therefore, the manufacturer should prepare traceable original test reports and design change records in advance. If the agent lacks sufficient technical understanding, the efficiency of deficiency communication will be greatly reduced.

Common Mistakes

• Choosing an agent only based on registration experience, without checking their professional background in medical device regulations and local licensing qualifications, resulting in poor dossier quality and repeated deficiencies.
• Fully delegating technical file preparation to the agent without retaining original data. When the agent leaves or the cooperation ends, the manufacturer cannot maintain the certificate or respond to regulatory inspections.
• Ignoring the responsibility clauses in the agent agreement, such as adverse event reporting timelines, change notification obligations, renewal reminders, data ownership, and confidentiality, leading to disputes later.
• Applying CE or FDA thinking to target countries, assuming that holding CE eliminates the need for localization, and not realizing that labels, IFUs, product names, and classifications may be completely different.
• Not evaluating the agent's knowledge of the latest regulations in the target country, especially new GHWP guidelines or national drug administration guidelines, causing outdated registration strategies.
• Focusing only on initial registration costs while ignoring post-market maintenance costs such as agent annual fees, renewal services, change registration, and vigilance system support, leading to budget overruns.
• Selecting agents with different backgrounds for each country without unified coordination, resulting in inconsistent technical file versions and conflicting registration timelines.

Manufacturer Preparation Checklist

• Clarify the target country and market scope; confirm whether the product falls under medical device regulation, determine the risk class and registration pathway.
• Review the inventory of existing certificates and documents (NMPA, CE, FDA, ISO 13485, MDSAP, etc.) and assess which can be used directly or require supplementation.
• Create a core technical file library with complete versions of original design files, test reports, risk management files, and clinical evaluation data, with controlled access.
• Develop a localization plan for labels and IFUs, specifying language, units of measure, symbols, company name, and address requirements.
• Define local agent selection criteria, including qualifications, regulatory experience, local government relationships, technical communication ability, available resources, and fee structure.
• Require the agent to provide case studies and team profiles, and verify their actual professional level via phone or video conference.
• Draft a detailed service agreement specifying responsibilities, scope of work, service period, remuneration, confidentiality, intellectual property, data ownership, termination conditions, and dispute resolution mechanisms.
• Develop a post-market work plan covering adverse event reporting, annual updates, change notifications, renewal applications, and regulatory inspection coordination.

AIMEILI's Perspective

From a regulatory consultancy point of view, the most common misjudgment is handing over all unfamiliar regulatory work to the local agent while forgetting that the manufacturer is the ultimate responsibility holder. Even if local law defines the agent as the 'license holder' or 'authorized representative', the manufacturer remains ultimately responsible for product safety, effectiveness, and compliance.

At an early stage, conduct a complete gap analysis, not just discuss pricing with agents. Confirm product classification, technical documentation differences, clinical data requirements, QMS recognition scope in each target market, and then identify the specific tasks requiring local agent participation. Only by breaking down the workload can you assess whether the agent's quote is reasonable and determine which services can be outsourced and which must be retained internally.

Many parts of existing documentation can be reused. For example, risk management files based on ISO 14971, biocompatibility reports based on ISO 10993, and safety test reports based on IEC 60601 are generally acceptable as the technical basis in most countries. However, labels, IFUs, intended use descriptions, and clinical claims must be localized according to target country regulations, not simply translated. Agents can provide language and regulatory support, but manufacturers should review final versions.

The local agent's importance is most evident in certificate control, changes, and renewals. If the agent is listed as the registrant on the certificate and the agreement does not specify certificate ownership and change rights, the manufacturer may lose the ability to exercise certificate rights after cooperation ends. Foreign manufacturers should treat the relationship with the local agent as a regulatory relationship, not ordinary outsourcing, and above all define the file transfer and certificate transfer procedure during agent changes.

For multi-country registration, manufacturers should establish a unified project management mechanism, using a core technical file library to generate corresponding submission packages for different countries. This avoids redundant preparation and deficiency risk. When selecting agents, try to choose agent groups that can operate collaboratively within the same region, or require each agent to use consistent technical file versions, with a periodic synchronization mechanism. This increases efficiency and reduces delays caused by version inconsistencies.

Frequently Asked Questions

Can a company apply for overseas registration without a local agent?

It depends on the target country's regulations. Some countries allow foreign manufacturers to apply directly in their own name, but most countries require a designated local agent, especially in GHWP member states, Southeast Asia, and the Middle East. For example, Saudi Arabia, UAE, Thailand, Indonesia, Malaysia, and others typically require a local authorized representative. Even in countries that allow direct application, post-market surveillance and communication require a local contact person, so in practice a local agent is usually needed.

What is the difference between a local agent and an authorized representative?

Strictly speaking, an 'authorized representative' is a concept commonly used in EU regulations, responsible for communicating on behalf of the foreign manufacturer with regulators and assuming certain legal liabilities. A 'local agent' is a broader term, referring to a local entity responsible for registration affairs, customs clearance, after-sales service, or post-market surveillance. Some countries treat them as equivalent, while others distinguish between them. Manufacturers should confirm the legal status and responsibility scope of the role as defined in the target country and specify this in the agreement.

How to evaluate the reliability of a local agent?

Consider several dimensions: registration qualification (whether legally registered locally); industry experience (whether they have handled similar rehabilitation device or active device registrations); regulatory competence (whether they can explain current regulations and update trends); communication ability (whether they can communicate technical issues with reviewers); and post-market services (whether they have adverse event reporting and emergency notification capabilities). Request the agent to provide information on previously approved products and verify with industry peers.

Continue Reading

Related Articles

• How to Prepare Clinical Evaluation Data for Overseas Registration of Rehabilitation Devices
• How to Prepare Performance Validation Data for Overseas Registration of Rehabilitation Devices
• How to Divide Responsibilities of Authorized Representatives for Overseas Registration of Imaging Equipment
• What to Prepare Before Renewal of Overseas Registration for Imaging Equipment

Content review and applicability boundary: Author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority to official regulatory authorities, international organizations, standards organizations, and public regulatory documents; industry media and project experience only for auxiliary judgment. Applicability boundary: This article is intended for early understanding, documentation preparation, and project planning, and does not replace the formal requirements, testing conclusions, or legal opinions of the target country's regulatory authority.